HLS Therapeutics (TSE:HLS) Trading Down 1.3% – Here’s What Happened

HLS Therapeutics Inc. (TSE:HLS)’s stock price dropped 1.3% during trading on Monday . The company traded as low as C$4.35 and last traded at C$4.41. Approximately 3,010 shares were traded during trading, a decline of 62% from the average daily volume of 8,021 shares. The stock had previously closed at C$4.47.

HLS Therapeutics Price Performance

The business has a 50 day simple moving average of C$4.55 and a 200 day simple moving average of C$4.62. The company has a debt-to-equity ratio of 75.00, a current ratio of 1.00 and a quick ratio of 1.01. The company has a market capitalization of C$136.05 million, a price-to-earnings ratio of -13.59 and a beta of -0.02.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Friday, May 15th. The company reported C($0.10) earnings per share for the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.The company had revenue of C$17.88 million for the quarter. As a group, equities analysts predict that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.